Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PROCEPT BioRobotics Corporation - Common Stock
(NQ:
PRCT
)
23.39
-0.85 (-3.51%)
Streaming Delayed Price
Updated: 12:23 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about PROCEPT BioRobotics Corporation - Common Stock
< Previous
1
2
3
Next >
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
April 22, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
April 09, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
March 23, 2026
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia
From
PROCEPT BioRobotics
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
March 12, 2026
UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
March 10, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
March 10, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
March 09, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm
March 08, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
February 26, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
February 25, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day
February 23, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
February 04, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
January 26, 2026
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
November 20, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
November 04, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
October 15, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
August 06, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
July 24, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
July 23, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
July 21, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
July 14, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
April 29, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
April 24, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
April 24, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
April 10, 2025
From
PROCEPT BioRobotics
Via
GlobeNewswire
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
March 24, 2025
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a...
From
PROCEPT BioRobotics
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
